Results 21 to 30 of about 1,137 (206)

Optimization of solubility studies performed in the context of BCS biowaiver monographs [PDF]

open access: green, 2022
Die vorliegende Dissertation stellt eine Methode zur Löslichkeitsbestimmung vor, die für die Anwendung im Rahmen von BCS-Biowaiver Monografien entwickelt wurde.
Plöger, Gerlinde Friederike
core   +2 more sources

Evaluation of Excipient Risk in BCS Class I and III Biowaivers. [PDF]

open access: hybridAAPS J, 2022
Abstract The objective of this review article is to summarize literature data pertinent to potential excipient effects on intestinal drug permeability and transit. Despite the use of excipients in drug products for decades, considerable research efforts have been directed towards evaluating their potential effects
Metry M, Polli JE.
europepmc   +5 more sources

Biowaiver Based on the Biopharmaceutical Classification System: Regulatory Basis and Limits of Scientific Interpretation (Review)

open access: diamondРегуляторные исследования и экспертиза лекарственных средств
INRODUCTION. Biowaiver procedure based on the biopharmaceutics classification system (BCS) is widely used in regulatory practice when assessing the bioequivalence of generic medicinal products (GMPs).
N. J. Dahma   +5 more
doaj   +2 more sources

Comprehensive Patterns Concerning BA/BE Studies and Biowaivers in the Regulatory Approval of Generic Pharmaceuticals in the United States, the EU, and India

open access: goldAdvances in Pharmacological and Pharmaceutical Sciences, Volume 2026, Issue 1, 2026.
This analysis studies the pharmaceutical approval policy regarding generics in the United States and European and Indian markets. Therapeutically equivalent generics are therefore considered safe, effective, and of comparable quality to their name‐brand counterparts.
Rakan Alsaqer   +10 more
wiley   +2 more sources

Challenges obtaining a biowaiver for topical veterinary dosage forms [PDF]

open access: yesJournal of Veterinary Pharmacology and Therapeutics, 2012
Baynes, R., Riviere, J., Franz, T., Monteiro‐Riviere, N., Lehman, P., Peyrou, M., Toutain, P.‐L. Challenges obtaining a biowaiver for topical veterinary dosage forms.J. vet. Pharmacol. Therap.35(Suppl. 1), 103–114.Obtaining a biowaiver for topical drugs used in veterinary species faces many of the same challenges associated with human topicals. However,
Baynes, Ronald E   +6 more
openaire   +6 more sources

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisone [PDF]

open access: yesJournal of Pharmaceutical Sciences, 2007
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisone are reviewed. Due to insufficient data prednisone cannot be definitively classified according to the current Biopharmaceutics Classification System (BCS) criteria as ...
Vogt, M   +8 more
openaire   +8 more sources

Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
This report summarizes the proceedings for day 2 sessions 1 and 3 of the 2‐day public workshop entitled “Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches,” a jointly sponsored workshop by the US Food and Drug ...
Fang Wu   +17 more
doaj   +2 more sources

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate [PDF]

open access: bronze, 2022
S.2-13Sitagliptin is an antihyperglycemic drug used in adults for the treatment of diabetes Type 2. Literature data and in-house experiments were applied in this monograph to assess whether methods based on the Biopharmaceutics Classification System (BCS)
Mehta, M.   +13 more
core   +2 more sources

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fexofenadine [PDF]

open access: bronze
29812993In this monograph, the potential use of methods based on the Biopharmaceutics Classification System (BCS) framework to evaluate the bioequivalence of solid immediate-release (IR) oral dosage forms containing fexofenadine hydrochloride as a ...
Langguth, Peter   +11 more
core   +2 more sources

Biowaiver monographs for immediate-release solid oral dosage forms: Lemborexant [PDF]

open access: bronzeJournal of Pharmaceutical Sciences
Lemborexant is a dual orexin receptor antagonist assigned to class II of the Biopharmaceutics Classification System (BCS). Thus, the ICH M9 Guideline excludes immediate-release (IR) solid oral dosage forms containing lemborexant from BCS-based biowaivers, irrespective of their in vitro dissolution behavior.
Beran, Kristian   +11 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy